FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4383892384> ?p ?o ?g. }

• W4383892384 endingPage "115622" @default.
• W4383892384 startingPage "115622" @default.
• W4383892384 abstract "Chagas disease (CD) is a neglected tropical disease endemic in 21 countries and affects about 8 million people around the world. The pharmacotherapy for this disease is limited to two drugs (Benznidazole and Nifurtimox) and both are associated with important limitations, as low cure rate in the chronic phase of the disease, high toxicity and increasing resistance by Trypanosoma cruzi. Recently, we reported a bioactive 1,2,3-triazole (compound 35) active in vitro (IC50 42.8 μM) and in vivo (100 mg/kg) against T. cruzi Y strains and preliminary in silico studies suggested the cysteine protease cruzain as a possible target. Considering these initial findings, we describe here the design and synthesis of new 1,2,3-triazoles derivatives of our hit compound (35). The triazoles were initially evaluated against healthy cells derived from neonatal rat cardiomyoblasts (H9c2 cells) to determine their cytotoxicity and against epimastigotes forms of T. cruzi Y strain. The most active triazoles were compounds 26 (IC50 19.7 μM) and 27 (IC50 7.3 μM), while benznidazole was active at 21.6 μM. Derivative 27 showed an interesting selectivity index considering healthy H9c2 cells (>77). Promising activities against trypomastigotes forms of the parasite were also observed for triazoles 26 (IC50 20.74 μM) and 27 (IC50 8.41 μM), mainly 27 which showed activity once again higher than that observed for benznidazole (IC50 12.72 μM). While docking results suggested cruzain as a potential target for these compounds, no significant enzyme inhibition was observed in vitro, indicating that their trypanocidal activity is related to another mode of action. Considering the promising in vitro results of triazoles 26 and 27, the in vivo toxicity was initially verified based on the evaluation of behavioral and physiological parameters, mortality, effect in body weight gain, and through the measurement of AST/ALT enzymes, which are markers of liver toxicity. All these evaluations pointed to a good tolerability of the animals, especially considering triazole 27. A reduction in parasitemia was observed among animals treated with triazole 27, but not among those treated with derivative 26. Regarding the dosage, derivative 27 (100 mg/kg) was the most active sample against T. cruzi infection, showing a 99.4% reduction in parasitemia peak. Triazole 27 at a dosage of 100 mg/kg influenced the humoral immune response and reduced myocarditis in the animals, bringing antibody levels closer to those observed among healthy mice. Altogether, our results indicate compound 27 as a new lead for the development of drug candidates to treat Chagas disease." @default.
• W4383892384 created "2023-07-12" @default.
• W4383892384 creator A5019071901 @default.
• W4383892384 creator A5019220562 @default.
• W4383892384 creator A5033922215 @default.
• W4383892384 creator A5048822704 @default.
• W4383892384 creator A5051821820 @default.
• W4383892384 creator A5055121303 @default.
• W4383892384 creator A5057144159 @default.
• W4383892384 creator A5059388710 @default.
• W4383892384 creator A5063393431 @default.
• W4383892384 creator A5081133980 @default.
• W4383892384 creator A5083247417 @default.
• W4383892384 date "2023-10-01" @default.
• W4383892384 modified "2023-09-30" @default.
• W4383892384 title "Design and synthesis of new 1,2,3-triazoles derived from eugenol and analogues with in vitro and in vivo activity against Trypanosoma cruzi" @default.
• W4383892384 cites W1790840956 @default.
• W4383892384 cites W1969794825 @default.
• W4383892384 cites W1971849220 @default.
• W4383892384 cites W2005796800 @default.
• W4383892384 cites W2019621761 @default.
• W4383892384 cites W2024102174 @default.
• W4383892384 cites W2050456292 @default.
• W4383892384 cites W2051324369 @default.
• W4383892384 cites W2052030759 @default.
• W4383892384 cites W2067954507 @default.
• W4383892384 cites W2070854001 @default.
• W4383892384 cites W2103941030 @default.
• W4383892384 cites W2123471676 @default.
• W4383892384 cites W2132609517 @default.
• W4383892384 cites W2169678694 @default.
• W4383892384 cites W2327321986 @default.
• W4383892384 cites W2564783762 @default.
• W4383892384 cites W2808947823 @default.
• W4383892384 cites W2867412178 @default.
• W4383892384 cites W2888777717 @default.
• W4383892384 cites W2921086158 @default.
• W4383892384 cites W2938132302 @default.
• W4383892384 cites W2978264348 @default.
• W4383892384 cites W2986971017 @default.
• W4383892384 cites W299593912 @default.
• W4383892384 cites W3047040612 @default.
• W4383892384 cites W3145730265 @default.
• W4383892384 cites W3171197551 @default.
• W4383892384 cites W3196167088 @default.
• W4383892384 cites W3196351047 @default.
• W4383892384 cites W3197852135 @default.
• W4383892384 cites W4206667749 @default.
• W4383892384 cites W4297260890 @default.
• W4383892384 cites W4308360243 @default.
• W4383892384 cites W4319317397 @default.
• W4383892384 cites W4321377497 @default.
• W4383892384 doi "https://doi.org/10.1016/j.ejmech.2023.115622" @default.
• W4383892384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37441850" @default.
• W4383892384 hasPublicationYear "2023" @default.
• W4383892384 type Work @default.
• W4383892384 citedByCount "1" @default.
• W4383892384 countsByYear W43838923842023 @default.
• W4383892384 crossrefType "journal-article" @default.
• W4383892384 hasAuthorship W4383892384A5019071901 @default.
• W4383892384 hasAuthorship W4383892384A5019220562 @default.
• W4383892384 hasAuthorship W4383892384A5033922215 @default.
• W4383892384 hasAuthorship W4383892384A5048822704 @default.
• W4383892384 hasAuthorship W4383892384A5051821820 @default.
• W4383892384 hasAuthorship W4383892384A5055121303 @default.
• W4383892384 hasAuthorship W4383892384A5057144159 @default.
• W4383892384 hasAuthorship W4383892384A5059388710 @default.
• W4383892384 hasAuthorship W4383892384A5063393431 @default.
• W4383892384 hasAuthorship W4383892384A5081133980 @default.
• W4383892384 hasAuthorship W4383892384A5083247417 @default.
• W4383892384 hasConcept C112418997 @default.
• W4383892384 hasConcept C136764020 @default.
• W4383892384 hasConcept C150903083 @default.
• W4383892384 hasConcept C159047783 @default.
• W4383892384 hasConcept C178790620 @default.
• W4383892384 hasConcept C185592680 @default.
• W4383892384 hasConcept C202751555 @default.
• W4383892384 hasConcept C207001950 @default.
• W4383892384 hasConcept C2776171842 @default.
• W4383892384 hasConcept C2776684476 @default.
• W4383892384 hasConcept C2777625466 @default.
• W4383892384 hasConcept C2777752497 @default.
• W4383892384 hasConcept C2780470866 @default.
• W4383892384 hasConcept C2781049234 @default.
• W4383892384 hasConcept C41008148 @default.
• W4383892384 hasConcept C55493867 @default.
• W4383892384 hasConcept C71928629 @default.
• W4383892384 hasConcept C86803240 @default.
• W4383892384 hasConcept C98274493 @default.
• W4383892384 hasConceptScore W4383892384C112418997 @default.
• W4383892384 hasConceptScore W4383892384C136764020 @default.
• W4383892384 hasConceptScore W4383892384C150903083 @default.
• W4383892384 hasConceptScore W4383892384C159047783 @default.
• W4383892384 hasConceptScore W4383892384C178790620 @default.
• W4383892384 hasConceptScore W4383892384C185592680 @default.
• W4383892384 hasConceptScore W4383892384C202751555 @default.
• W4383892384 hasConceptScore W4383892384C207001950 @default.
• W4383892384 hasConceptScore W4383892384C2776171842 @default.

• next